A year ago, Moderna was not on anyone’s “Most Likely to Succeed” list.
As the Cambridge biotech approached its 10th year, the company had yet to get a single product approved for sale by government regulators. Investors weren’t particularly hot on its potential, either ― after going public in December 2018, Moderna’s stock price hadn’t done much over the ensuing 12 months.
Then came the COVID-19 pandemic.
Read the full story.
|
|
